Atopic Dermatitis

These data from investigators at Trinity College Dublin highlighted the immune response mechanisms visible in children with atopic dermatitis.

During this interview segment, Browning highlighted the impact of a future FDA acceptance of tapinarof for atopic dermatitis as well as the next milestones in regulatory approval.

In this interview, Browning discusses his team’s trial data and the implications of the FDA’s decision to accept the supplemental new drug application for tapinarof as an eczema treatment.

The decision by Eli Lilly to resubmit lebrikizumab to the FDA for adults and adolescents with eczema is expected to receive a response in the second half of the year.

The announcement by Dermavant followed positive findings from the ADORING trials on tapinarof and an open label extension for children aged 2 - 17.

This observational cohort study looked at the link between obesity and eczema, highlighting regional differences in the skin disease and obesity’s interdependence.

This analysis highlighted several trends in search volume regarding eczema, including correlations with weather and climate.

New phase 3b/4 trial data compared both drugs efficacy and safety profiles for eczema patients, looking at adults and adolescents.

Eblasakimab shows promising itch relief in dupilumab-experienced atopic dermatitis patients, with significant reductions in symptoms observed.

This post-AAD interview with Chovatiya covered takeaways regarding recent data on upadacitinib for vitiligo, tapinarof for eczema, and lutikizumab for hidradenitis suppurativa.

New data suggest children with atopic dermatitis and comorbid ADHD are nearly 3 times more likely to struggle with memory compared to those with just ADHD.

Alexis discusses clinical and demographic hurdles in treating skin of color for conditions like atopic dermatitis, and the potential of research like that being done in tapinarof cream 1%.

Alexis spoke in this AAD interview about his team’s results regarding lebrikizumab for adults and adolescents with moderate-to-severe atopic dermatitis and skin of color.

New global data suggest children with moderate to severe atopic dermatitis may experience stunted growth due to the effect of their disease on sleep, as well as use of certain therapies.

Another segment of Silverberg’s interview at AAD 2024 featured a discussion on safety data and the larger implications of these phase 3 findings for eczema management.

This interview at AAD featured a discussion with Silverberg on nemolizumab’s efficacy and safety at Week 48 among patients with moderate-to-severe atopic dermatitis.

In a phase 3 trial that featured approximately half of participants with skin of color, tapinarof cream 1.0% provided consistent benefit for patients identified as White, Black, or Asian.

A secondary analysis from TRuE-AD3 shows ruxolitinib cream significantly benefits pediatric atopic dermatitis patient-reported outcomes.

The pioneer in neuroimmune research and itch physiology discusses how treatment innovation has evolved dermatology—and what still needs to be changed in practice.

A new analysis of the phase 3 ADORING 3 extension trial involved a large, diverse population and the analysis showed that 91% of eligible participants from previous phases rolled over into this trial.

In this discussion, Jonathan Silverberg described his team’s new phase 3 findings presented at AAD 2024 regarding upadacitinib and its impact on minimal disease activity in eczema patients.

Lawrence Eichenfield, MD, reviews prescription and at-home care strategies for pediatric atopic dermatitis, as well as the best measures of disease monitoring.

These data suggest that, among children with atopic dermatitis and ADHD or other learning disabilities, an assessment for impairment of their cognitive abilities may need prioritization.

These findings, to be presented at AAAAI, may allow for greater awareness among clinicians when prescribing eczema therapies.

These findings, to be presented at AAAAI, highlight the importance of labeling different cleansing products used by consumers with eczema.

This research also included results from a sub-analysis of non-responders with hand eczema to dupilumab and upadacitinib.

In addition to the newly-accepted BLA in the US, the European Medicines Agency also accepted the drug’s Marketing Authorization Application for both conditions.

In this interview, Eichenfield discussed the recent pooled analysis from two phase 3 studies looking at once-daily, topical roflumilast for patients 6 and older with eczema.

In an interview, Andrew Blauvelt, MD, MBA, provides further perspective on the approval of roflumilast topical foam, 0.3% (Zoryve) and full publication of phase 3 STRATUM data.

Andrea Nguyen, PA, shares her clinical pearls on taking care of patients with AD.